Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

3.000 +0.040 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 550,703
Open 2.950
Bid (Size) 3.000 (2)
Ask (Size) 3.030 (3)
Prev. Close 2.960
Today's Range 2.880 - 3.010
52wk Range 1.850 - 3.220
Shares Outstanding 99,161,234
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
From Arbutus Biopharma Corporation
Via Globe NewsWire

Performance

YTD
+34.53%
+34.53%
1 Month
+9.49%
+9.49%
3 Month
+28.76%
+28.76%
6 Month
+59.57%
+59.57%
1 Year
+3.81%
+3.81%

More News

Read More
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Biopharma's Return On Capital Employed Insights
Via Benzinga
Recap: Arbutus Biopharma Q2 Earnings
Via Benzinga
Arbutus to Participate in Three Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Announces Resignation of Board Member
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via Globe NewsWire
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
From Arbutus Biopharma Corporation
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
Via Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
Via Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.